For decades, the pathology of Alzheimer's disease has been associated with dysfunction of cholinergic signaling; however, the cellular mechanisms by which nicotinic acetylcholine receptor (nAChR) function is impaired in Alzheimer's disease are as yet unknown. The most significant genetic risk factor for the development of Alzheimer's disease is inheritance of the ⑀4 allele of apolipoprotein E (apoE). Recent data have demonstrated the ability of apoE-derived peptides to inhibit nAChRs in rat hippocampus. In the current study, the functional interaction between nAChRs and apoE-derived peptides was investigated in Xenopus oocytes expressing selected nAChRs. Both a 17-amino acid peptide fragment, apoE [133][134][135][136][137][138][139][140][141][142][143][144][145][146][147][148][149] , and an eight-amino acid peptide, apoE 141-148 , were able to maximally block acetylcholine (ACh)-mediated peak current responses for homomeric ␣7 nAChRs. ApoE peptide inhibition was dose-dependent and voltage-and activity-independent. The current findings suggest that apoE peptides are noncompetitive for acetylcholine and do not block functional ␣-bungarotoxin binding. ApoE peptides had a significantly decreased ability to inhibit ACh-mediated peak current responses for ␣4␤2 and ␣2␤2 nAChRs. Amino acid substitutions in the apoE peptide sequence suggest that the arginines are critical for peptide blockade of the ␣7 nAChR. The current data suggest that apoE fragments can disrupt nAChR signaling through a direct blockade of ␣7 nAChRs. These results may be useful in elucidating the mechanisms underlying memory loss and cognitive decline seen in Alzheimer's disease as well as aid in the development of novel therapeutics using apoE-derived peptides.
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Apolipoprotein E (apoE) is the principal apolipoprotein synthesized in the brain, and it is implicated as a risk factor in a variety of central nervous system disorders, including Alzheimer's disease (AD), and response to traumatic brain injury. ApoE is a 299-amino acid protein that, in the brain, is synthesized and secreted primarily by astrocytes (Pitas et al., 1987) . ApoE binds to low-density lipoprotein (LDL) receptors and historically is known to be involved with lipid metabolism and cholesterol transport. There are three isoforms of apoE (apoE2, apoE3, and apoE4), of which the apoE4 gene is associated with an increased risk of developing both familial and sporadic late-onset AD (Corder et al., 1993; Rebeck et al., 1993) . ApoE4 has been shown to colocalize with both A␤ plaques and neurofibrillary tangles, and evidence suggests that apoE4 may be associated with the progressive loss of cognitive function in AD (for review, see Marques and Crutcher, 2003) . Several hypotheses have emerged to account for apoE in the development of AD (Bales et al., 2002; Harris et al., 2003) ; however, none of these has yet provided a clear understanding of the role of apoE in the pathology of AD. ApoE is also a risk factor in several other conditions, including cognitive impairment: after traumatic brain injury, because of the progression of Parkinson's disease, and during normal aging (Friedman et al., 1999; Tang et al., 2002; Howieson et al., 2003) .
Proteolytic fragments of apoE, including the N-terminal thrombin cleavage fragment of 22 kDa, have been shown to be increased in the brain and cerebrospinal fluid of AD patients (Marques et al., 1996) . Both the full-length apoE, after proteolysis, and this N-terminal truncated apoE have been shown to cause neurotoxicity under a variety of experimental conditions (Marques et al., 1996; Michikawa and Yanagisawa, 1998 ). In addition, synthetic peptides derived from the LDL receptor binding domain of apoE have been shown to demonstrate similar neurotoxic effects (Clay et al., 1995; Tolar et al., 1997) . Previous work has shown that apoE peptides can also mimic the actions of the holoprotein in terms of binding to LDL receptor-related protein and protecting against NMDA-mediated excitotoxicity (Aono et al., 2003; Croy et al., 2004) . In addition, apoE mimetic peptides have demonstrated potential therapeutic usefulness in head trauma and after ischemic injury (Lynch et al., 2005; McAdoo et al., 2005) ; however, the cellular mechanisms underlying this benefit have not been identified in detail.
Neuronal nicotinic acetylcholine receptors (nAChRs) are involved in a variety of normal brain functions, including cognitive tasks, reward systems, and neuronal development (Jones et al., 1999) . Dysregulation of nAChR signaling has long been associated with multiple pathologies, including AD, schizophrenia, epilepsy, and Parkinson disease (for review, see Levin, 2002; Picciotto and Zoli, 2002; Raggenbass and Bertrand, 2002) . For example, selective neurodegeneration of cholinergic neurons occurs in AD and is evident by decreases in both choline acetyltransferase and acetylcholinesterase (AChE) activity as well as a decrease in nAChR number in the brains of AD patients (Davies and Maloney, 1976; Araujo et al., 1989) . In AD patients, administration of either nicotine or nAChR agonists can enhance performance on cognitive tasks (Jones et al., 1992; White and Levin, 1999) . Moreover, of the drugs approved to date to treat AD, all are AChE inhibitors with the exception of memantine, an NMDA receptor antagonist (for review, see Lleo et al., 2006) . Despite the past few decades of investigation, the direct cellular mechanisms by which nAChR function is impaired in AD are as yet unknown.
Recent work has demonstrated that apoE-derived peptides from the LDL receptor binding region inhibit native ␣7-containing nAChRs expressed on interneurons in rat hippocampal slices and that this inhibition was specific for excitatory receptors in the superfamily of ligand-gated ion channels (Klein and Yakel, 2004) . The current study probes the functional interaction between apoE-derived peptides and nAChRs expressed in Xenopus oocytes. The selectivity of apoE peptides for ␣7-and non-␣7-containing nAChRs was investigated as well as the sequence specificity for apoE peptide interaction with nAChRs. The nature of the apoE peptide/nAChR interaction was also explored. The current data support the hypothesis that apoE-derived peptides disrupt cholinergic signaling through a direct blockade of ␣7 nAChRs.
Materials and Methods
Peptide Synthesis. ApoE-derived peptides were synthesized by Sigma-Genosys (The Woodlands, TX) at a purity of 95% and reconstituted in either sterile, deionized water or dimethyl sulfoxide, yielding stock concentrations of 15 to 20 mM. Stock solutions were stored at Ϫ20°C and diluted to desired concentrations on the day of the experiment. The peptides used in this study were acetylated at the amino terminus and amide-capped at the carboxyl terminus, except for ApoE [133] [134] [135] [136] [137] [138] [139] [140] , which contained a free amino terminus. Pentalysine was purchased from Sigma-Aldrich (St. Louis, MO) and stored at Ϫ20°C (50 mM).
Oocyte Preparation. Female Xenopus laevis frogs were anesthetized in cold water containing 0.2% metaaminobenzoate, and the spinal cord was severed. Oocytes were dissected and defolliculated by treatment with collagenase B (2 mg/ml; Roche Diagnostics, Indianapolis, IN) and trypsin inhibitor (1 mg/ml; Invitrogen, Carlsbad, CA) for 2 h. Oocytes were maintained in solution containing: 82.5 mM NaCl, 2.5 mM KCl, 1 mM Na 2 HPO 4 , 3 mM NaOH, 5 mM HEPES, 1 mM CaCl 2 , 1 mM MgCl 2 , 2.5 mM pyruvic acid, and 0.05 mg/ml gentamicin sulfate with constant rotation at 18°C. mRNA for each of the nAChR subunits was transcribed from plasmids using mMessage mMachine 17 kit from Ambion (Austin, TX) according to the manufacturer's instructions. The total amount of RNA injected for ␣7 nAChR subunits was 50 ng, and for ␣4, ␣2, and ␤2 subunits was 12.5 ng each. Recordings were made 3 to 7 days post-RNA injection.
Oocyte Electrophysiology. Current responses were obtained by two-electrode voltage-clamp recording at a holding potential of Ϫ60 mV (unless otherwise stated) using a GeneClamp 500 and pClamp 8 software (Molecular Devices, Sunnyvale, CA). Electrodes contained 3 M KCl and had a resistance of Ͻ1 M⍀. ACh and peptides were prepared daily in bath solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES) from frozen stocks. ACh was applied for various time periods using a synthetic quartz perfusion tube (0.7 mm i.d.) operated by a computer-controlled valve. Peptides were bath-applied. Data were analyzed using pClamp 8, Excel (Microsoft, Redmond, WA), and Prism4 (GraphPad Software Inc., San Diego, CA). Peak current responses to each dose of apoE peptide or ACh were averaged, and the mean Ϯ S.E.M were analyzed by nonlinear regression using a logistic equation
). For dose-response curves, the bottom limit was set to zero, and IC 50 values are presented with 95% confidence intervals. Data for ACh dose-response curves were normalized to the peak current response at 1 mM ACh control. Multiple group comparisons were preformed by one-way analysis of variance followed by a Tukey's post hoc analysis to make specific comparisons between individual values (Origin 6; OriginLab Corp., Northampton, MA). Significance was defined at p Ͻ 0.05. Data are reported as mean Ϯ S.E.M. of multiple experiments (see Results for n values). For ␣-bungarotoxin (␣-BgTx) competition experiments, apoE peptides (10 M) or MLA (10 nM) was bath-applied for 10 min, followed by coapplication of ␣-BgTx (10 nM) with either apoE peptides or MLA for an additional 10 min, and subsequently followed by washout with bath solution. The concentrations of antagonists were chosen using a two-ligand receptor occupancy equation (Kenakin, 2004) , with K D values for ␣-BgTx and MLA of approximately 5 and 2 nM, respectively (http://pdsp.cwru.edu/pdsp.asp), so that approximately 89% of nAChRs would be occupied by apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] , 77% by apoE [141] [142] [143] [144] [145] [146] [147] [148] , and 71% by MLA when in combination with ␣-BgTx. Circular Dichroism Spectroscopy. CD spectra were recorded between 195 and 260 nm on a Jasco 810 spectrometer (Jasco, Tokyo, Japan) using 0.1-cm path length cells. Peptides were diluted from stock to 150 M in buffer containing 20 mM sodium phosphate, pH 6.0, 100 mM sodium chloride, and 40% trifluoroethanol (TFE). The ␣-helical content of the peptides was determined from the ellipticities at 222 nm using the empirical relationship fraction helix ϭ (Ϫ[⌰]222 Ϫ 2340)/30,300.
Results

ApoE Peptides Inhibit ␣7 nAChRs Expressed in
Xenopus Oocytes. The ability of synthetic apoE peptides, containing the LDL receptor binding region, to modulate nAChRs expressed in Xenopus oocytes was examined. Homomeric ␣7 nAChRs were expressed, and the effects of apoE peptides on ACh-induced responses were determined. Receptors were activated by the rapid application of ACh (2 mM) at a holding potential of Ϫ60 mV (Fig. 1) . The 17-amino acid peptide apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] (3 M) inhibited ACh-induced ␣7 nAChR peak current responses by 91 Ϯ 3% (n ϭ 12), which was reversible upon washout (Fig. 1a) . This inhibition was dose-dependent with an IC 50 value of 445 nM (95% CI ϭ 349 -566 nM; Fig. 2 ).
To determine the active sequence of this 17-mer apoE peptide, two peptides of eight amino acids, apoE [133] [134] [135] [136] [137] [138] [139] [140] and apoE 141-148 , were tested. Interestingly, the N-terminal portion of the peptide apoE 133-140 caused significantly less inhibition of ACh-mediated responses (16 Ϯ 3% at 3 M; n ϭ 8) compared with apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] , whereas the C-terminal portion of the peptide apoE 141-148 was able to inhibit ␣7 nAChRmediated responses similar to apoE 133-149 (85 Ϯ 1% at 3 M; n ϭ 15) (Fig. 1, b and c) . Correspondingly, the ability of apoE [141] [142] [143] [144] [145] [146] [147] [148] to block ␣7 nAChR function was dose-dependent (IC 50 ϭ 1.30 M; 95% CI ϭ 1.07-1.56 M; Fig. 2) , and the peak current response returned upon washout of the peptide (Fig. 1b) . Maximum peptide inhibition generally occurred within the time period between agonist applications (i.e., 2 min), a time required for full recovery from ␣7 receptor desensitization. Application of apoE peptides did not affect the baseline current responses (data not shown).
ApoE Peptides Inhibit ␣7 nAChR Function in a Noncompetitive and Voltage-Independent Manner. ACh dose-response curves were generated in the presence or absence of apoE peptides (0.3 M) to determine the mechanism of interaction between the apoE peptide and the ␣7 nAChR. For each ACh concentration tested, both apoE 133-149 and apoE 141-148 displayed comparable inhibition of peak current responses as well as similar EC 50 values (control ϭ 120 M, apoE 133-149 ϭ 116 M, and apoE 141-148 ϭ 116 M) for activation of the ␣7 nAChR by ACh (n ϭ 2-11 oocytes for each ACh concentration; Fig. 3b ). These data suggest that both apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] and apoE [141] [142] [143] [144] [145] [146] [147] [148] are interacting with the channel in a noncompetitive manner.
To determine whether apoE peptides were competing with the ␣-BgTx binding site, we used a method similar to previous studies demonstrating that preincubation with ligands competitive for the ␣-BgTx binding site can preclude the very slow recovery from ␣-BgTx functional block (Ellison et al., 2003) . A 10-minute bath application of 10 nM ␣-BgTx was enough to block peak ACh current responses at ␣7 nAChRs by 91 Ϯ 3% (n ϭ 3; Fig. 4a ). This inhibition was slow to wash out with only 15 Ϯ 3% of the peak response returning after 20 min. However, when oocytes were pretreated for 10 min with 10 nM MLA, a known reversible competitive antagonist of ␣7 nAChRs, followed by 10-min coapplication of MLA and ␣-BgTx, the peak ACh current response recovered more quickly [i.e., by 78 Ϯ 6% (n ϭ 4) in 20 min; Fig. 4b ]. These jpet.aspetjournals.org data suggest that MLA and ␣-BgTx are competing for the same site on ␣7 nAChRs, as expected. However, when oocytes were pretreated with either 10 M apoE 133-149 or apoE [141] [142] [143] [144] [145] [146] [147] [148] followed by coapplication with ␣-BgTx, the peak current response did not recover upon washout (6 Ϯ 2 and 18 Ϯ 6%, respectively, n ϭ 3; Fig. 4, c and d) , suggesting that these apoE peptides are blocking at a site distinct from ␣-BgTx.
Another potential mechanism of block was an open-channel block, which is generally considered to be highly voltageand use-dependent (Colquhoun and Ogden, 1988; Maconochie and Knight, 1992) . The ability of apoE peptides to block ␣7 nAChR function was not significantly different at ϩ30 versus Ϫ60 mV. ApoE 133-149 (3 M) blocked the peak ACh current response at ϩ30 mV by 95 Ϯ 1% (n ϭ 6) and apoE 141-148 (3 M) blocked 77 Ϯ 3% (n ϭ 6) (data not shown), similar to the block at Ϫ60 mV, suggesting that these peptides inhibit through a voltage-independent mechanism. Furthermore, when apoE 133-149 was applied for 10 min before ACh application, the initial current response showed maximal inhibition, indicating that there was no use-dependent component of the peptide block (data not shown). Together, these data suggest that apoE peptides are not blocking ␣7 nAChRs through an open channel block mechanism.
ApoE Peptides Preferentially Inhibit ␣7-versus Non-␣7-Containing nAChRs. To determine the specificity of the apoE peptide interaction with ␣7-versus non-␣7-containing receptors, ␣4␤2 and ␣2␤2 nAChRs were expressed in Xenopus oocytes. Compared with homomeric ␣7 nAChRs, both ␣4␤2 and ␣2␤2 nAChRs activate more slowly and do not desensitize in the continued presence of agonist. Both apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] and apoE [141] [142] [143] [144] [145] [146] [147] [148] showed significantly less inhibition of ACh-mediated peak current responses for ␣4␤2 and ␣2␤2 nAChRs (Fig. 5) . ApoE 133-149 (3 M) blocked ␣4␤2 and ␣2␤2 nAChRs by 43 Ϯ 6% (n ϭ 9) and 71 Ϯ 4% (n ϭ 6) of control values, respectively. Interestingly, the shorter eightamino acid peptide apoE 141-148 demonstrated more selectivity for ␣7 nAChRs, inhibiting ACh-induced peak currents by only 23 Ϯ 6% (n ϭ 9) for ␣4␤2 receptors and 8 Ϯ 4% (n ϭ 6) for ␣2␤2 nAChRs. These data suggest that the LDL receptorderived apoE peptides are less effective at inhibiting non-␣7 receptor mediated responses, with apoE 141-148 demonstrating pronounced selectivity for ␣7 nAChRs.
ApoE Peptide Sequence Requirements for nAChR Inhibition. To determine the minimally active peptide, as well as peptide sequence specificity, synthetic peptides of varying length and sequence were tested. A five-amino acid peptide apoE 144 -148 had nominal ability to block ACh peak current responses for ␣7 nAChRs (25 Ϯ 4% at 3 M; n ϭ 6; Fig. 6 ). Both random and nonrandom scrambled peptides also demonstrated limited inhibition (35 Ϯ 4 and 23 Ϯ 4%; n ϭ 10 and 8, respectively; Fig. 6 ). Similarly, pentalysine displayed minimal block of ␣7 nAChRs function (10 Ϯ 2% at at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from 3 M; n ϭ 6). These data suggest that both peptide sequence and length are important for block of ␣7 nAChRs.
In addition, substitutions at certain residues of both apoE 133-149 and apoE 141-148 were tested to probe the key amino acid residues responsible for apoE inhibition of ␣7 nAChR function. First, the two positively charged lysines (positions 143 and 146) were substituted with leucines in both apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] and apoE [141] [142] [143] [144] [145] [146] [147] [148] . These altered peptides were able to block ACh peak current responses for ␣7 nAChRs similar to their native counterparts (93 Ϯ 7 and 74 Ϯ 8%; n ϭ 7 and 8, respectively; Fig. 6 ). Although replacing these basic lysines with the nonpolar leucines had no effect on maximal inhibition, this change dramatically decreased the rate of block for ␣7 nAChRs from less than 2 min to more than 10 min. For both of these peptides, the inhibition was reversible upon washout (Fig. 7) . Next, the introduction of a negative charge at these two lysine positions by substitution with glutamate completely abrogated the ability of the peptide to inhibit ␣7 nAChRs responses (2 Ϯ 1% at 3 M; n ϭ 5; Fig. 6 ). Finally, there are three positively charged arginines in the active 8-mer peptide. Altering two of the three arginines to leucines (positions 142 and 147) significantly reduced the ability of apoE [141] [142] [143] [144] [145] [146] [147] [148] to inhibit peak ␣7 nAChR responses (7 Ϯ 2% at 3 M; n ϭ 4).
Circular Dichroism Measurements. The apoE peptides used in this study are derived from an ␣-helical portion of the apoE protein that includes the LDL receptor binding region. To determine the ␣-helical propensity of the peptides, we assessed the helical content in the presence of 40% TFE, a solvent that can stabilize ␣-helical regions of a peptide (Supplemental Fig. 1 ). ApoE 133-149 exhibited ␣-helicity of 47%, whereas apoE 141-148 only demonstrated 13% helicity in the presence of TFE. ApoE 133-140 , along with both of the scrambled peptides, had minimal ␣-helical tendencies (Ͻ15%). Interestingly, although unable to block ACh responses, the altered apoE peptide containing glutamate residues had a propensity to helicity of 37%, similar to the active apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] (Table 1) .
Discussion
The present study demonstrates that peptides derived from the LDL receptor binding domain of apoE inhibit ␣7-containing nAChRs expressed in Xenopus oocytes. Both a 17-amino acid peptide fragment of apoE (apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] ) and a shorter eight-amino acid peptide (apoE 141-148 ) were able to block ACh-mediated peak current responses for ␣7 nAChRs. ApoE peptide inhibition was dose-dependent, with IC 50 values in the high nanomolar to micromolar range, and similar to those found in hippocampal interneurons (Klein and Yakel, 2004) . Neither a peptide containing amino acids 133-140 nor a five-amino acid peptide, apoE 144 -148 , was able to block ACh peak current responses for ␣7 receptors, indicating activity is preserved within the eight-residue fragment apoE [141] [142] [143] [144] [145] [146] [147] [148] .
Similar apoE peptides have been used in several studies investigating various physiological effects. Studies have demonstrated that apoE-derived peptides can inhibit lym- 6 . Effect of apoE peptide amino acid substitutions and sequence on inhibition of ␣7 nAChRs. ApoE 133-149 and the C-terminal portion of the peptide (apoE 141-148 ) dramatically inhibited ACh-evoked responses, whereas the N-terminal portion of the peptide (apoE 133-140 ) was almost completely inactive. A shorter five-amino acid peptide (apoE 144 -148 ) was unable to significantly inhibit ␣7 nAChR-mediated responses. Both random and nonrandom scrambled peptides had a significantly reduced ability to block ␣7 nAChR function. Pentalysine was unable to inhibit ␣7 nAChR-mediated responses. The introduction of glutamate residues significantly decreased peptide activity, whereas replacing arginine with leucine residues also dramatically reduced the ability of the apoE peptide to inhibit ␣7 nAChRs. ‫,ء(‬ p Ͻ 0.05, compared with both apoE 133-149 and apoE [141] [142] [143] [144] [145] [146] [147] [148] ). All peptide effects are shown at 3 M.
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at ASPET Journals on October 18, 2017 jpet.aspetjournals.org phocyte proliferation without loss of cell viability (Clay et al., 1995) , induce neurite degeneration (Tolar et al., 1997) , and block both neuronal death and NMDA-mediated calcium influx (Aono et al., 2003) . Interestingly, it was shown that apoE 133-149 could block NMDA-induced excitotoxicity, whereas the shorter peptide, apoE 139 -149 , did not retain this protective function (Aono et al., 2003) . This is in contrast to the data presented here with the ␣7 nAChR where apoE 141-148 preserved activity. Intriguingly, there is recent evidence that as an alternative to the cholinergic hypothesis of Alzheimer's disease glutamatergic dysfunction may play a role in the etiology of the disease (for review, see Doraiswamy, 2003) . Perhaps most important has been the demonstration that apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] can improve both motor and cerebellar function after closed head injury in mice (Lynch et al., 2005) as well as reduce brain injury following perinatal hypoxia-ischemia in rats (McAdoo et al., 2005) . These data suggest the immense potential therapeutic usefulness of apoE-derived peptides.
Additional studies by other groups have been performed using synthetic peptides that are tandem repeats of the LDL receptor binding region of the protein. These experiments have somewhat contradictory results to the monomeric peptide data since tandem repeat peptides cause neurite degeneration and neuronal cell death in multiple cell preparations (Crutcher et al., 1994; Tolar et al., 1997 Tolar et al., , 1999 Qiu et al., 2003) and increase intracellular calcium concentration through NMDA receptors (Tolar et al., 1999; Qiu et al., 2003) . These discrepancies could be because of the precise peptide used as well as because of differences in peptide exposure time. In addition, the majority of apoE peptides used to date do not include the polymorphic sites of the apoE protein and therefore do not address directly apoE isoform-specific affects. However, differences at the polymorphic sites (positions 112 and 158) of apoE have been demonstrated to affect the LDL receptor binding region (Weisgraber et al., 1982) , suggesting that apoE genotype may still play a role in peptide action.
The current data support the hypothesis that the apoE peptides derived from the LDL receptor binding domain interact directly with the nAChR to modulate its function. ApoE peptide inhibition of ␣7 nAChR responses was unaltered by changes in voltage; in addition, the ability of apoE 133-149 to inhibit ACh-mediated peak current responses was unaffected by previous activity of the channel. These data indicate that apoE peptide inhibition of nAChR function is not activity dependent and that the peptides are not functioning as open channel blockers. The relative inhibition of apoE peptides for ACh-mediated peak current responses at ␣7 nAChR was similar across a range of ACh concentrations, suggesting the peptides do not compete for the ACh binding site. These experiments were conducted under conditions in which the ligand and receptor were not at equilibrium; therefore, the possibility that apoE peptides interact with nAChRs in a competitive manner could not be ruled out. However, further data were also consistent with a noncompetitive interaction. ApoE peptides were unable to block functional ␣-BgTx binding, indicating that the peptides do not interact with ␣7 nAChRs in a manner that is competitive for the ␣-BgTx binding site. These data would suggest that apoE peptides interact with ␣7 nAChRs either at a site other than the traditional ligand binding site or at the interface between subunits at a distinct microsite that does not preclude ␣-BgTx binding. In this manner, apoE peptides may interact with ␣7 nAChRs in a mode similar to the ␣-conotoxin ImII (Ellison et al., 2003) . Together, the current data suggest that apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] and apoE 141-148 act as noncompetitive antagonists of ␣7 nAChRs.
To investigate the specificity of the actions of apoE peptides at various subtypes of nAChRs, the ability of the peptides to block ␣4␤2 and ␣2␤2 nAChRs in Xenopus oocytes was also tested. Both apoE [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] and apoE 141-148 (3 M) had a significantly decreased ability to inhibit ␣4␤2 and ␣2␤2 peak ACh current responses, suggesting apoE peptides are somewhat selective for ␣7-containing nAChRs over non-␣7 receptors. Interestingly, compared with apoE 133-149 , the shorter apoE 141-148 had a more pronounced selectivity for ␣7-con- taining over non-␣7-containing nAChRs. This suggests that there may be more than one mode of interaction for apoE peptides and nAChRs. To further probe the amino acid requirements and sequence specificity of the apoE peptide necessary for inhibition of ␣7 nAChR responses, several peptides with substitutions in particular residues were assessed. Scrambled (both random and nonrandom) and shorter (apoE 144 -148 ) peptides had a significantly reduced ability to inhibit ␣7 nAChRs. However, the scrambled peptides retained minimal activity, denoting that although the presence of basic amino acids is not the defining characteristic for peptide activity, positive charges may contribute to the ability of apoE peptides to block ␣7 nAChR function. Substitutions in the apoE peptide sequence suggest that the arginines are critical for peptide blockade of the ACh peak response, whereas the lysines are not. In addition, the decreased rate of inhibition for the lysine-to-leucine-substituted peptides again suggests the possibility of multiple modes of interaction between apoE peptides and ␣7 nAChRs. This may be a sign of multiple binding sites or peptide-specific interactions with particular receptor residues at a single binding site. Overall, these data indicate that both the sequence and charge of amino acids in the peptide play a role in receptor blockade; however, the specific amino acid sequence is critical for complete inhibition of ␣7-mediated responses.
Similar to previous work (Clay et al., 1995; Aono et al., 2003) , CD measurements revealed that apoE peptides are capable of adopting an ␣-helical structure, with the longer apoE 133-149 peptide demonstrating a higher propensity for ␣-helical formation than the shorter apoE [141] [142] [143] [144] [145] [146] [147] [148] . However, the current data suggest that ␣-helicity is not required for blockade of nAChR function since the inactive arginine-toleucine substitution displayed a higher percentage of ␣-helicity than the maximally active apoE [141] [142] [143] [144] [145] [146] [147] [148] . It should be noted that all CD measurements were made in the presence of ␣-helical promoting TFE and that the two-dimensional structure of these peptides has yet to be determined under physiological conditions or upon binding to nAChRs.
There are an increasing number of reports of small brainderived peptides interacting with neuronal nAChRs to modulate function. Similar to the data presented here, ␤-amyloid 1-42 has been shown to block ␣4␤2 receptors in a noncompetitive manner and at higher concentrations to block ␣7 receptors (Wu et al., 2004) . Calcitonin gene-related peptide fragments have been shown to either inhibit or facilitate non-␣7-containing nAChR responses, depending on the peptide (Di Angelantonio et al., 2002) . Recently, a peptide derived from the C-terminal region of AChE was demonstrated to modulate ␣7 but not ␣4␤2 nAChRs expressed in oocytes. In contrast to the apoE peptides, this AChE peptide potentiated ACh responses at low concentrations (1 nM), while blocking ACh-mediated currents at higher concentrations (1 M) (Greenfield et al., 2004) . Together, these findings suggest that the interaction between small peptides and nAChRs may be a unique way to modulate nAChR signaling in the brain. Specific peptide entities may be useful both as scientific tools as well as potential therapeutic agents. For example, after insult, apoE4 has been demonstrated to decrease microglial activation less than apoE2 or E3. However, apoE peptides containing the LDL receptor binding region can suppresses microglial activation, potentially compensating for the apoE4 genotypic deficits (Laskowitz et al., 2001 ). In addition, as mentioned above, the use of apoE-derived peptides may represent a novel therapeutic strategy (Lynch et al., 2005; McAdoo et al., 2005) , and the current results may provide insight into the mechanisms underlying the potential therapeutic benefit of these peptides. In addition, protein fragments created in vivo may in part underlie the progressive pathology of multiple neurodegenerative processes, and use of peptides that mimic these fragments may help to elucidate the etiology of the disease. The data presented here demonstrate that apoE-derived peptides disrupt nAChR signaling by directly inhibiting ion channel activation. The current findings may have considerable implications both in elucidating the mechanisms underlying the memory loss and cognitive decline seen in AD as well as in the development of novel therapeutics through the use of apoE-derived peptides to regulate nAChR signaling.
